Clonazepam Dosing Guidelines
For seizure disorders in adults, start clonazepam at 1.5 mg/day divided into three doses, titrate by 0.5-1 mg every 3 days, with a maximum of 20 mg/day; for panic disorder, start at 0.25 mg twice daily and increase to a target of 1 mg/day after 3 days, with a maximum of 4 mg/day. 1
Adult Dosing
Seizure Prophylaxis
Starting dose: 1.5 mg/day divided into three doses (e.g., 0.5 mg three times daily)
Titration: Increase by 0.5-1 mg every 3 days until seizures are controlled or side effects emerge
Maintenance: Individualized based on response; typical range 0.1-0.2 mg/kg/day
Maximum dose: 20 mg/day 1
The FDA label provides clear guidance that multiple anticonvulsants increase CNS depression risk, so careful monitoring is essential when adding clonazepam to existing regimens 1. Research supports that clonazepam at 1 mg every 8 hours IV is effective for busulfan-induced seizure prophylaxis in adults 2.
Anxiety/Panic Disorder
Starting dose: 0.25 mg twice daily
Target dose: 1 mg/day (reached after 3 days)
Titration beyond 1 mg/day: If needed, increase by 0.125-0.25 mg twice daily every 3 days
Maximum dose: 4 mg/day 1
The 1 mg/day dose is optimal - research demonstrates this provides the best balance of efficacy and tolerability, with higher doses (2-4 mg/day) showing no additional benefit but increased adverse effects 3. At 1 mg/day, 74% of patients became panic-attack free versus 56% on placebo 1.
To minimize somnolence, consider giving the full dose at bedtime rather than divided dosing 1.
Pediatric Dosing
Seizure Disorders (Children up to 10 years or 30 kg)
Starting dose: 0.01-0.03 mg/kg/day (not exceeding 0.05 mg/kg/day), divided into 2-3 doses
Titration: Increase by no more than 0.25-0.5 mg every third day
Maintenance: 0.1-0.2 mg/kg/day, divided into three equal doses (largest dose before bedtime if unequal)
Goal: Control seizures before side effects become limiting 1
Research in prepubertal children with panic-like symptoms showed successful treatment with 0.5-3 mg daily, with rapid symptom control and no adverse effects reported 4.
Panic Disorder in Children
No established pediatric dosing - clonazepam lacks clinical trial data for panic disorder in patients under 18 years 1.
Special Populations
Elderly Patients
Start with low doses and observe closely 1. For anxiety/agitation in elderly patients, NICE guidelines recommend lorazepam 0.25-0.5 mg (maximum 2 mg in 24 hours) rather than standard adult doses 5. Apply this conservative approach to clonazepam by:
- Starting at 0.25 mg twice daily for panic disorder
- Starting at 0.5 mg three times daily (1.5 mg total) for seizures
- Slower titration intervals (every 5-7 days rather than every 3 days)
Hepatic Impairment
Clonazepam undergoes extensive hepatic metabolism (>98% metabolized, <2% excreted unchanged) 1. The FDA label explicitly states that liver disease will likely impair elimination and caution is required 1.
Practical approach:
- Mild-moderate impairment: Start at 50% of standard dose, titrate more slowly
- Severe impairment: Avoid or use only under specialist supervision with close monitoring
Recent 2026 pharmacokinetic data confirms that hepatic impairment significantly alters benzodiazepine disposition, though specific clonazepam dose adjustments remain unstudied 6.
Renal Impairment
No specific dose adjustment required - clonazepam is primarily hepatically metabolized with minimal renal excretion 1. However, active metabolites may accumulate, so monitor for increased sedation in severe renal disease.
Discontinuation
Taper gradually to avoid withdrawal seizures and rebound anxiety:
- Panic disorder: Decrease by 0.125 mg twice daily every 3 days until completely withdrawn 1
- Seizure disorders: Reduce by 0.25-0.5 mg every 3-7 days
Research shows that with proper tapering, most patients tolerate discontinuation without severe withdrawal, though some symptom worsening occurs 3.
Critical Prescribing Considerations
Avoid underdosing: Despite established guidelines, benzodiazepines are frequently underdosed in status epilepticus with detrimental consequences 7. However, recent data suggests commonly recommended loading doses may exceed what's needed in some patients 7.
Monitor for tolerance: While evidence argues against tolerance development in most epilepsy patients on clobazam 8, this remains a theoretical concern with chronic clonazepam use.
Respiratory depression risk: Combining clonazepam with opioids or other CNS depressants significantly increases apnea risk 9. Have respiratory support available and monitor oxygen saturation closely.
Pharmacokinetics: Peak plasma levels occur 1-4 hours post-dose, elimination half-life is 30-40 hours, and 85% protein binding means drug interactions are possible 1.